Last checked at 10 Feb 2016 07:00
Faron Pharmaceuticals Ltd
("Faron" or the "Company")
Notice of Preliminary Results
TURKU - FINLAND, 10 February 2016 - Faron Pharmaceuticals Ltd ("Faron") (LON: FARN), the clinical stage biopharmaceutical company, will announce its Preliminary Results for the year ended 31st December, 2015 on Thursday 10th March, 2016.
Dr Markku Jalkanen, Chief Executive Officer, will host a presentation for analysts at 9am GMT on the day at Hume Brophy offices, 55 King William Street, London EC4R 9AD.
For more information contact:
Faron Pharmaceuticals Ltd
Katja Wallenlind
Phone +358 (50) 577 4807E-mail: katja.wallenlind@faronpharmaceuticals.com
Cairn Financial Advisers LLP, Nominated Adviser
Emma Earl, Tony Rawlinson and Rebecca Anderson
Phone: +44 207 148 7900
Whitman Howard Limited, Nominated Broker
Niall Devins, Francis North
Phone: +44 207 659 1234
Hume Brophy, PR
Mary Clark, Eva Haas, Hollie Vile
Phone: +44 207 862 6390
E-mail: faron@humebrophy.com
About Faron Pharmaceuticals Oy
Faron is a drug discovery and development company focused on creating novel treatments for medical conditions with significant unmet needs. The Company is based in Turku, Finland. The Company currently has a pipeline of products focusing on acute organ traumas, cancer immunotherapy and vascular damage. The Company's lead candidate Traumakine®, has been developed to treat acute respiratory distress syndrome ("ARDS"), a rare, severe, life threatening medical condition for which there is currently no approved pharmaceutical treatment. Traumakine® is now in a pan-European pivotal Phase III study (INTEREST). Besides Traumakine®, Faron's pipeline consists of early stage assets including a pre-clinical anti-Clever-1 antibody named Clevegen. Clevegen is focused on converting the immune environment around a tumour from being immune suppressive to immune stimulating.
Further information is available at www.faronpharmaceuticals.com.